期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

双膦酸盐治疗血液透析患者继发性甲状旁腺功能亢进研究进展 被引量：2

下载PDF
导出
摘要 继发性甲状旁腺功能亢进是慢性肾衰竭的严重并发症之一，重度继发性甲状旁腺功能亢进可表现为顽固性高钙血症、高磷血症、甲状旁腺增生、皮肤瘙痒、骨痛、骨折、心血管钙化、甚至身高下降（退缩人综合征）等，严重影响患者生活质量。双膦酸盐具有抑制破骨细胞、对抗骨吸收、增加骨量等作用，目前广泛应用于骨质疏松、变形性骨炎和恶性骨病等旧J。但由于双膦酸盐类药物主要通过肾脏代谢，限制了其在慢性肾脏病继发性甲状旁腺功能亢进中的应用，本文就双膦酸盐治疗血液透析患者继发性甲状旁腺功能亢进的研究进展作如下综述。
作者 刘慢慢 陈德君
机构地区 浙江省台州医院肾内科
出处 《中国中西医结合肾病杂志》 2014年第6期552-554,共3页 Chinese Journal of Integrated Traditional and Western Nephrology
关键词 继发性甲状旁腺功能亢进 双膦酸盐类药物 血液透析患者 治疗 甲状旁腺增生 严重并发症 慢性肾衰竭 心血管钙化
分类号 R692.5 [医药卫生—泌尿科学]
  • 相关文献

参考文献23

  • 1Jamaluddin E J, Gafor AHA, Yean LC, et al. Oral paricalcitol ver- sus oral calcitriol in continuous ambulatory peritoneal dialysis pa- tients with secondary hyperparathyroidism. Clinical and Experi- mental Nephrology,2013.1 -8.
  • 2Bhuriya R, Singh M, Molnar J, et al. Bisphosphonate use in women and the risk of atrial fibrillation:a systematic review and meta - analysis. International Journal of Cardiology, 2010, 142 (3) :213 - 17.
  • 3VanBeek E, Hoekstra M, Vande Ruit M, et al. Structural require- ments for bisphosphanates actions in vitro. J Bone Miner Res, 1994,9 : 1875.
  • 4Huang CY,Zheng CM, Wu CC, et al. Effects of Pamidronate and Calcitriol on the Set Point of the Parathyroid Gland in Postmeno- pausal Hemodialysis Patients with Secondary Hyperparathyroid- ism. Nephron Clinical Practice, 2013,122 ( 3 - 4) : 93 - 101.
  • 5Moe S, Drtieke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease : Improving Global Outcomes (KDIGO). Kidney Int.2006.69 ( 11 ) : 1945 - 1953.
  • 6Fraser WD. Hyperparathyroidism. The Lancet, 2009,374 (9684) : 145 - 158.
  • 7Nagano N, Nemeth EF. Functional proteins involved in regulation of intracellular Ca2 for drug development: the extracellular calci- um receptor and an innovative medical approach to control sec- ondary hyperparathyroidism by calcimimetics. J Pharmacol Sci, 2005,97(3) :355 -360.
  • 8Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture : a growing concern. Kidney Int, 2008,74 ( 6 ) : 721 -731.
  • 9Fanning M. Use of bisphosphonates in renal impairment. Austral- ian Pharmacist,2010,29(7) :598.
  • 10Hirschberg R. Renal complications from bisphosphonate treat- ment. Current Opinion in Supportive and Palliative Care,2012,6(3) :342-347.

同被引文献33

  • 1National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis ,2003,42 (4 Suppl 3 ) : S1 - 201.
  • 2Moe SM, DrUeke T, Lameire N, et al. Chronic kidney disease - mineral - bone disorder: a new paradigm. Ad- Chronic Kidney Dis,2007,14 ( 1 ) :3 - 12.
  • 3Sun LY, Wang M, Yang L. Study of calcium - phosphorous me- tabolism and intact parathyroid hormone le-els in end stage renal disease patients. Beijing Da Xue Xue Bao, 2005,37 ( 2 ) : 147 - 150.
  • 4Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and mobidity in maintenance hemodialysis. J Am Soc Nephrol, 200d, 15 ( 8 ) :2208 - 2218.
  • 5Block GA, Port FK. Re - e-aluation of risks associated with hy- perphosphatemia and hyperparathyroidism in dialysis patients?: recommendations for a change in management. Am J Kidney Dis, 2000,35(6) :1226 - 1237.
  • 6Marco MP, Cra-er L, Betriu A, et al. Higher impact of mineral metabolism on cardio-ascular, mortality in a European hemodialy- sis population. Kidney Int Suppl,2003, ( 85 ) : S111 - S114.
  • 7Noordzij M, Kore-aar JC, Boeschoten EW, et al. Netherlands Co- operati-e Study on the Adequacy of Dialysis (NECOSAD) Study Group. The kidney disease outcomes quality initiati-e(K/DOQI) guidelines for bone metabolism and disease in CKD : association with mortality in dialysis patients. Am J Kidney Dis, 2005,46 (5) :925 -932.
  • 8Goodman WG. Medical management of secondary hyperparathy- roidism in chronic renal failure. Nephrol Dial Transplant, 2003, 18 (suppl 3) :2 -8.
  • 9Le-ine BS, Song M. Pharmacokinetics and efficacy of pulse oral -ersus intra-enous calcitriol in hemodialysis patients. J Am Soc Nephrol, 1996,7 (3) :488 - 496.
  • 10Stubbs JR, Wetmore JB. Does it matter how parathyroid hormone le-els are suppressed in secondary hyperparathyroidism? Semin Dial,2011,24 (3) :298 - 306.

引证文献2

二级引证文献5

中国中西医结合肾病杂志
2014年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部